An interventional study of Cardiovalve Transfemoral Mitral Valve in Mitral Regurgitation and Mitral Valve Disease, sponsored by Cardiovalve Ltd.. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Cardiovalve Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.
Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 35th largest by planned enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2018, is one of 39 with no phase, reaches primary completion later than 12 of the 31 other live ones, and was the 39th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:
University Medical Center Mainz · Sites in Germany
Ages 18+
Jena University Hospital · Sites in Germany
Ages 18+
Medical University of Vienna · Sites in Germany, Austria, Italy and 1 more country
Ages 18+
4C Medical Technologies, Inc. · Sites in Germany, United States, Canada and 4 more countries
Ages 18+
LMU Klinikum · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 4 3
First in 2006; this study’s year is marked. 5 started in 2018.
This study's planned enrollment of 30 is below the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 113 across the 48 interventional studies, 214 across the 33 observational. Of the 37 that completed or were terminated, 12 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 81 have an industry lead sponsor. The 10 most frequent:
Cardiovalve Ltd. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Cardiovalve Ltd. has 4 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Mitral Valve Insufficiency with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04029363HighLife SASExpanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk | 2026-12-15 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
| NCT06634121LMU KlinikumEfficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population | 2027-04-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety of the Cardiovalve Transfemoral Mitral Valve System with its associated procedure, and observe the device performance in reducing mitral regurgitation. Data collected in this clinical study will include 30-day safety and performance, and long-term clinical outcomes over a follow-up of 2 years.
The Cardiovalve offers a mitral replacement valve delivered through a transfemoral access and transseptal approach, and is intended to reduce mortality and adverse event rates in selected patients for whom surgical options are not feasible.
Innovation: A truly trans femoral, trans venous delivery of the prosthetic mitral valve which minimizes procedural risk. The Cardiovalve Implant features a dual nitinol frame for robust radial strength with decoupling of the atrial flange and ventricular portion which contains 24 grasping legs designed for atraumatic anchoring of the device to the native mitral annulus. Valve leaflets are made of bovine pericardium. The Cardiovalve implant has a very low left ventricle (LV) protrusion footprint thus reducing the risk of LV outflow tract obstruction and/or interference with the LV. The Cardiovalve delivery system (DS) is designed for transfemoral delivery of the Implant with transseptal access to the left atrium. The catheter assembly is used to center the implant relative to the native mitral valve plane and align it with the left ventricual apex-to-base axis. After valve implantation, the delivery system is withdrawn.
General Inclusion Criteria
The subject commits to return for the scheduled post-operative follow-up visits at the hospital.
Anatomical Inclusion Criteria
Cardiovascular Exclusion Criteria
CRT/ICD implant within 30 days
Anatomical Exclusion Criteria (assessed by pre-procedural imaging)
Severe tricuspid or aortic valve disease
General Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mitral replacement valve delivered through a transfemoral access and transseptal approach
Device: Cardiovalve Transfemoral Mitral Valve
The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
The primary safety endpoint is freedom from all-cause mortality and major adverse events
Freedom from all-cause mortality, all cause hospitalization, major adverse cardiac events (MACE), major device- or procedure- related serious adverse events
Time frame: 30 days, 3 Months, 6 Months, 12 Months, and 24 Months
Technical success
Technical success: I. Absence of procedural mortality II. Delivery and deployment of the device in the correct position and retrieval of delivery catheter, without significant mitral stenosis, LVOT obstruction or paravalvular MR documented by intraoperative imaging \[Time Frame:Intraoperative\] III. Freedom from emergency surgery or reintervention related to the device or access procedure \[Time Frame: 30 days\]
Time frame: Intraoperative, 30 Days
Device Success
I. Absence of procedural mortality or stroke II. Proper placement and positioning of the device III. Freedom from unplanned surgical or interventional procedures related to the device or access procedure
Time frame: Intraoperative
Device Success
IV. Continued intended safety and performance of the device including: 1. No evidence of structural or functional failure 2. No specific device-related technical failure issues and complications 3. Reduction in MR grade to either optimal (0+ to trace) or acceptable (reduced by at least 1 grade from baseline with no more than 2+ MR). Number of patients with reduction in MR grade from baseline
Time frame: 30 days, 3 Months, 6 Months, 12 Months, and 24 Months
Patient Success
I. Device success (either optimal or acceptable) II. Patient returned to the pre-procedural setting * III. Freedom from rehospitalizations or reinterventions for the underlying condition (e.g., mitral regurgitation, worsening of heart failure) * IV. Improvement from baseline in NYHA functional class Number of patients with improvement in NYHA class * V. Six minute walk test Increase in distance (m) from baseline * VI. Improvement from baseline in quality-of-life (Kansas City Cardiomyopathy Questionnaire improvement by ≥ 10)
Time frame: 30 days, 3 Months, 6 Months, 12 Months, and 24 Months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2018 (actual). Primary completion is estimated for Dec 2026, 104 months after the start.
Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 104 months is above that.
Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiovalve Ltd.